The extended funding round follows Avea's recent launch of six groundbreaking products that have solidified the company's position as a leader in the longevity science market across Europe. The newly raised funds will be allocated towards various strategic initiatives, including expanding production capabilities, strengthening sales and marketing initiatives, reinforcing distribution networks across key European markets and conducting our first human studies. A significant portion of the investment will be dedicated to establish Avea's presence in Asia, capitalizing on the growing demand for longevity science products in this market.
Avea's innovative product portfolio, consisting of science-backed longevity solutions, has garnered exceptional acclaim and consumer demand since its recent introduction to the market. Among these highly effective products is the Collagen Activator, developed in partnership with scientists from the ETH Zurich. This product has demonstrated unprecedented efficacy, exhibiting up to four times the effectiveness of regular collagen when it’s about activating your body’s own collagen production. The Collagen Activator, currently pending patent approval, has accumulated remarkable results for Avea customers, further solidifying Avea's position as a trusted brand in the industry.
"We are excited about the opportunities that lie ahead as we expand into the APAC market," commented Tobias Reichmuth, Founding Partner at Maximon "With our well-established reputation in Europe and the outstanding results achieved with our products, including the highly acclaimed Collagen Activator, we are confident that Avea's longevity science solutions will resonate with consumers in the APAC region, empowering them to lead healthier and more fulfilling lives."
(Press release / SK)
Please login or sign up to comment.
Commenting guidelines